FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib

被引：0
|
作者：
Lixia Gao
Xuli Wang
Yaoliang Tang
Shuang Huang
Chien-An Andy Hu
Yong Teng
机构：
[1] Augusta University,Department of Oral Biology, Dental College of Georgia
[2] University of Utah,Department of Radiology and Imaging Sciences, School of Medicine
[3] University of Utah,Experimental Therapeutics Program, Huntsman Cancer Institute
[4] Augusta University,Vascular Biology Center, Department of Medicine, Medical College of Georgia
[5] University of Florida College of Medicine,Department of Anatomy and Cell Biology
[6] University of New Mexico School of Medicine,Department of Biochemistry and Molecular Biology
[7] Augusta University,Department of Biochemistry and Molecular Biology, Medical College of Georgia
来源：
Journal of Experimental & Clinical Cancer Research | / 36卷
关键词：
FGF19; FGFR4; Hepatocellular carcinoma; Drug resistance; Sorafenib; Synergistic effect;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] FGF401: A reversible-covalent inhibitor of FGFR4 for the treatment of hepatocellular carcinoma
    Fairhurst, Robin
    Knoepfel, Thomas
    Furet, Pascal
    Buschmann, Nicole
    Leblanc, Catherine
    Mah, Robert
    Kiffe, Michael
    Graus-Porta, Diana
    Weiss, Andreas
    Kinyamu-Akunda, Jacqueline
    Wartmann, Markus
    Trappe, Joerg
    Gabriel, Tobias
    Hofmann, Francesco
    Sellers, William
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [42] FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis
    Tianli Chen
    Hongda Liu
    Zengli Liu
    Kangshuai Li
    Ruixi Qin
    Yue Wang
    Jialiang Liu
    Zhipeng Li
    Qinglun Gao
    Chang Pan
    Fan Yang
    Wei Zhao
    Zongli Zhang
    Yunfei Xu
    Oncogene, 2021, 40 : 4941 - 4953
  • [43] FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis
    Chen, Tianli
    Liu, Hongda
    Liu, Zengli
    Li, Kangshuai
    Qin, Ruixi
    Wang, Yue
    Liu, Jialiang
    Li, Zhipeng
    Gao, Qinglun
    Pan, Chang
    Yang, Fan
    Zhao, Wei
    Zhang, Zongli
    Xu, Yunfei
    ONCOGENE, 2021, 40 (30) : 4941 - 4953
  • [44] FGF19/FGFR4信号通路在肝细胞癌中的研究进展
    王磊
    陈欣菊
    现代肿瘤医学, 2019, 27 (16) : 2949 - 2954
  • [45] Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease
    Chen, Qiang
    Jiang, Yuan
    An, Yuan
    Zhao, Na
    Zhao, Yang
    Yu, Chundong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 409 (04) : 651 - 656
  • [46] H3B6527, a selective and potent FGFR4 inhibitor for FGF19-driven hepatocellular carcinoma
    Selvaraj, Anand
    Corcoran, Erik
    Coffey, Heather
    Prajapati, Sudeep
    Hao, Ming-Hong
    Larsen, Nicholas
    Tsai, Jennifer
    Satoh, Takashi
    Ichikawa, Kana
    Joshi, Julie Jaya
    Hurley, Raelene
    Wu, Jeremy
    Huang, Chia-Ling
    Bailey, Suzanna
    Karr, Craig
    Kumar, Pavan
    Rimkunas, Victoria
    Mackenzie, Crystal
    Rioux, Nathalie
    Kim, Amy
    Akare, Sandeep
    Lai, George
    Yu, Lihua
    Fekkes, Peter
    Wang, John
    Warmuth, Markus
    Smith, Peter
    Reynolds, Dominic
    CANCER RESEARCH, 2017, 77
  • [47] H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
    Joshi, Jaya Julie
    Coffey, Heather
    Corcoran, Erik
    Tsai, Jennifer
    Huang, Chia-Ling
    Ichikawa, Kana
    Prajapati, Sudeep
    Hao, Ming-Hong
    Bailey, Suzanna
    Wu, Jeremy
    Rimkunas, Victoria
    Karr, Craig
    Subramanian, Vanitha
    Kumar, Pavan
    MacKenzie, Crystal
    Hurley, Raelene
    Satoh, Takashi
    Yu, Kun
    Park, Eunice
    Rioux, Nathalie
    Kim, Amy
    Lai, Weidong G.
    Yu, Lihua
    Zhu, Ping
    Buonamici, Silvia
    Larsen, Nicholas
    Fekkes, Peter
    Wang, John
    Warmuth, Markus
    Reynolds, Dominic J.
    Smith, Peter G.
    Selvaraj, Anand
    CANCER RESEARCH, 2017, 77 (24) : 6999 - 7013
  • [48] Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
    Hatlen, Megan A.
    Schmidt-Kittler, Oleg
    Sherwin, Cori Ann
    Rozsahegyi, Emily
    Rubin, Nooreen
    Sheets, Michael P.
    Kim, Joseph L.
    Miduturu, Chandrasekhar
    Bifulco, Neil
    Brooijmans, Natasja
    Shi, Hongliang
    Guzi, Timothy
    Boral, Andy
    Lengauer, Christoph
    Dorsch, Marion
    Kim, Richard D.
    Kang, Yoon-Koo
    Wolf, Beni B.
    Hoeflich, Klaus P.
    CANCER DISCOVERY, 2019, 9 (12) : 1686 - 1695
  • [49] Correction: FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis
    Tianli Chen
    Hongda Liu
    Zengli Liu
    Kangshuai Li
    Ruixi Qin
    Yue Wang
    Jialiang Liu
    Zhipeng Li
    Qinglun Gao
    Chang Pan
    Fan Yang
    Wei Zhao
    Zongli Zhang
    Yunfei Xu
    Oncogene, 2023, 42 : 3219 - 3219
  • [50] Influence of Heparin Mimetics on Assembly of the FGF•FGFR4 Signaling Complex
    Saxena, Krishna
    Schieborr, Ulrich
    Anderka, Oliver
    Duchardt-Ferner, Elke
    Elshorst, Bettina
    Gande, Santosh Lakshmi
    Janzon, Julia
    Kudlinzki, Denis
    Sreeramulu, Sridhar
    Dreyer, Matthias K.
    Wendt, K. Ulrich
    Herbert, Corentin
    Duchaussoy, Philippe
    Bianciotto, Marc
    Driguez, Pierre-Alexandre
    Lassalle, Gilbert
    Savi, Pierre
    Mohammadi, Moosa
    Bono, Francoise
    Schwalbe, Harald
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (34) : 26628 - 26640
12345